|
شركة Yifan Pharmaceutical Co.، Ltd. (002019.SZ) تقييم DCF
CN | Healthcare | Drug Manufacturers - General | SHZ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Yifan Pharmaceutical Co., Ltd. (002019.SZ) Bundle
Simplify Yifan Pharmaceutical Co., Ltd. (002019SZ) valuation with this customizable DCF Calculator! Featuring real Yifan Pharmaceutical Co., Ltd. (002019SZ) financials and adjustable forecast inputs, you can test scenarios and uncover Yifan Pharmaceutical Co., Ltd. (002019SZ) fair value in minutes.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5,186.8 | 5,400.4 | 4,409.0 | 3,836.6 | 4,022.2 | 3,797.0 | 3,584.5 | 3,383.9 | 3,194.5 | 3,015.7 |
| Revenue Growth, % | 0 | 4.12 | -18.36 | -12.98 | 4.84 | -5.6 | -5.6 | -5.6 | -5.6 | -5.6 |
| EBITDA | 1,306.6 | 1,342.6 | 492.6 | 471.0 | -483.5 | 466.9 | 440.7 | 416.1 | 392.8 | 370.8 |
| EBITDA, % | 25.19 | 24.86 | 11.17 | 12.28 | -12.02 | 12.3 | 12.3 | 12.3 | 12.3 | 12.3 |
| Depreciation | 161.5 | 186.4 | 212.9 | 237.9 | 279.8 | 186.5 | 176.0 | 166.2 | 156.9 | 148.1 |
| Depreciation, % | 3.11 | 3.45 | 4.83 | 6.2 | 6.96 | 4.91 | 4.91 | 4.91 | 4.91 | 4.91 |
| EBIT | 1,145.1 | 1,156.1 | 279.6 | 233.1 | -763.3 | 280.4 | 264.7 | 249.9 | 235.9 | 222.7 |
| EBIT, % | 22.08 | 21.41 | 6.34 | 6.08 | -18.98 | 7.38 | 7.38 | 7.38 | 7.38 | 7.38 |
| Total Cash | 1,562.7 | 1,370.5 | 1,336.1 | 1,239.3 | 773.4 | 1,043.0 | 984.6 | 929.5 | 877.5 | 828.4 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 1,000.4 | 1,102.2 | 1,145.1 | 1,257.9 | 1,208.8 | 975.9 | 921.3 | 869.7 | 821.0 | 775.1 |
| Account Receivables, % | 19.29 | 20.41 | 25.97 | 32.79 | 30.05 | 25.7 | 25.7 | 25.7 | 25.7 | 25.7 |
| Inventories | 598.2 | 583.9 | 663.9 | 831.0 | 928.6 | 623.8 | 588.9 | 556.0 | 524.8 | 495.5 |
| Inventories, % | 11.53 | 10.81 | 15.06 | 21.66 | 23.09 | 16.43 | 16.43 | 16.43 | 16.43 | 16.43 |
| Accounts Payable | 419.0 | 381.2 | 350.9 | 288.4 | 431.4 | 313.9 | 296.3 | 279.8 | 264.1 | 249.3 |
| Accounts Payable, % | 8.08 | 7.06 | 7.96 | 7.52 | 10.72 | 8.27 | 8.27 | 8.27 | 8.27 | 8.27 |
| Capital Expenditure | -866.1 | -715.7 | -571.7 | -542.3 | -504.1 | -528.4 | -498.9 | -470.9 | -444.6 | -419.7 |
| Capital Expenditure, % | -16.7 | -13.25 | -12.97 | -14.13 | -12.53 | -13.92 | -13.92 | -13.92 | -13.92 | -13.92 |
| Tax Rate, % | 36.59 | 36.59 | 36.59 | 36.59 | 36.59 | 36.59 | 36.59 | 36.59 | 36.59 | 36.59 |
| EBITAT | 968.5 | 1,036.0 | 369.3 | 189.1 | -484.1 | 234.8 | 221.7 | 209.3 | 197.6 | 186.5 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -915.7 | 381.4 | -142.7 | -457.6 | -614.0 | 313.1 | -29.2 | -27.6 | -26.0 | -24.6 |
| WACC, % | 8.3 | 8.32 | 8.38 | 8.28 | 8.17 | 8.29 | 8.29 | 8.29 | 8.29 | 8.29 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 207.2 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | -26 | |||||||||
| Terminal Value | -595 | |||||||||
| Present Terminal Value | -400 | |||||||||
| Enterprise Value | -192 | |||||||||
| Net Debt | 1,297 | |||||||||
| Equity Value | -1,489 | |||||||||
| Diluted Shares Outstanding, MM | 1,225 | |||||||||
| Equity Value Per Share | -1.22 |
What You Will Receive
- Authentic Yifan Pharmaceutical Financial Data: Pre-loaded with Yifan’s historical and projected financials for comprehensive analysis.
- Customizable Template: Easily adjust key variables such as revenue growth, WACC, and EBITDA %.
- Instant Calculations: Watch Yifan Pharmaceutical’s intrinsic value refresh in real-time as you make adjustments.
- Professional Valuation Tool: Tailored for investors, analysts, and consultants in search of precise DCF results.
- User-Friendly Interface: Easy-to-follow layout and clear guidance for users of all skill levels.
Key Features
- Customizable Forecast Inputs: Adjust key metrics such as sales growth, gross margin %, and R&D expenses.
- Instant DCF Valuation: Quickly computes intrinsic value, NPV, and other key financial outputs.
- High-Precision Accuracy: Incorporates Yifan Pharmaceutical’s actual financial data for realistic valuation insights.
- Effortless Scenario Analysis: Easily test various assumptions and analyze different outcomes.
- Efficiency Booster: Streamlines the valuation process, eliminating the need for complex model construction from the ground up.
How It Functions
- 1. Access the Template: Download and open the Excel file containing Yifan Pharmaceutical Co., Ltd.'s preloaded data.
- 2. Adjust Assumptions: Modify key inputs such as growth rates, WACC, and capital expenditures.
- 3. Instant Results: The DCF model automatically calculates the intrinsic value and NPV.
- 4. Explore Scenarios: Analyze various forecasts to evaluate different valuation outcomes.
- 5. Present with Assurance: Share professional valuation insights to back your decisions regarding Yifan Pharmaceutical Co., Ltd. (002019SZ).
Why Select This Calculator for Yifan Pharmaceutical Co., Ltd. (002019SZ)?
- Reliable Data: Utilize authentic financial metrics from Yifan Pharmaceutical for trustworthy valuation outcomes.
- Flexible Options: Modify essential inputs such as growth rates, WACC, and tax rates to fit your forecasts.
- Efficiency Boost: Pre-configured calculations save you the hassle of starting from the ground up.
- Expert-Level Tool: Tailored for investors, analysts, and consultants focusing on the pharmaceutical sector.
- Easy to Use: User-friendly design and clear, step-by-step guidance ensure accessibility for all users.
Who Can Benefit from This Product?
- Investment Professionals: Develop comprehensive and accurate valuation models for analyzing portfolios involving Yifan Pharmaceutical Co., Ltd. (002019SZ).
- Corporate Finance Departments: Evaluate valuation scenarios to inform strategic decisions within the organization.
- Consultants and Financial Advisors: Deliver precise valuation insights for clients interested in Yifan Pharmaceutical Co., Ltd. (002019SZ).
- Students and Educators: Utilize real industry data to enhance learning and practice in financial modeling.
- Healthcare Industry Enthusiasts: Gain an understanding of how pharmaceutical companies like Yifan are assessed and valued in the market.
Contents of the Template
- Operating and Balance Sheet Data: Pre-loaded historical and forecast data for Yifan Pharmaceutical Co., Ltd. (002019SZ), including metrics such as revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated worksheet for calculating the Weighted Average Cost of Capital (WACC), featuring inputs like Beta, the risk-free rate, and stock price.
- DCF Valuation (Unlevered and Levered): Customizable Discounted Cash Flow models that provide intrinsic value estimates along with thorough calculations.
- Financial Statements: Pre-filled annual and quarterly financial statements to facilitate detailed analysis.
- Key Ratios: A collection of profitability, leverage, and efficiency ratios specific to Yifan Pharmaceutical Co., Ltd. (002019SZ).
- Dashboard and Charts: An illustrative summary of valuation results and underlying assumptions for easier assessment of outcomes.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.